• Endocrine and Autoimmune Disorders Conference - All Presentations

    Original Date: November 6-7, 2021

    This discounted package includes all of the individual presentations from the conference, which are listed below.

    12.0 CEUs (including 7.5 general and 4.5 pharmacy) approved by OBNM

  • Post-Covid, Microbiome and Autoimmunity

    Presenter: Heather Zwickey, PhD
    Original Date: November 6, 2021

    A lot of research has been devoted to COVID over the past 20 months. In this seminar, we will examine the research related to COVID, Post-COVID Syndrome, and Autoimmunity. In the first part of the seminar, we will discuss what we know now about the immune response to COVID. We’ll include how having pre-existing inflammation can affect that response. We’ll then examine how the inflammatory response can impact existing autoimmunity. We will discuss whether COVID or COVID vaccines can trigger new autoimmunity, and how they impact existing autoimmunity.
    We will then examine the role the microbiome plays in autoimmunity and how COVID affects the microbiome. We will examine whether post-COVID could be microbiome related, drawing relationships between post-COVID and Lyme disease. Finally, we will discuss therapeutic approaches to Post-COVID that are microbiome-centric.
    This seminar will discuss the pharmaceuticals:
    Biologic anti-IL-6,
    Biologic anti-IL-1,
    Biologic anti-TNF
    Pfizer vaccine,
    Moderna vaccine
    J&J vaccine
    vaccine boosters
    Medications that impact microbiome

    1.0 pharmacy and 0.5 general CEUs approved by OBNM

  • Compounding for Autoimmune Disorders: LDN, Topicals and More

    Presenter: Natalie Gustafson, PharmD
    Original Date: November 6, 2021

    Compounding offers many opportunities to help support patients with various endocrine, autoimmune and inflammatory conditions. For instance, many autoimmune conditions can be benefited with the use of Low Dose Naltrexone (LDN). Traditionally used to help patients struggling with addiction to opiates or alcohol, at lower dosages LDN has been shown to have a significant impact on immune function and inflammation. It has been studied and used clinically in Multiple Sclerosis (MS), Crohn’s, Systemic Sclerosis, Hashimoto’s, Lupus, Rheumatoid Arthritis and more. Understanding its mechanisms of action and analyzing literature as well as clinical practice can help practitioners ascertain which patients might benefit from LDN as part of their treatment protocol.
    In addition, there are many other ways compounded medications can benefit these patients and we will discuss these as well. Customized topical formulations can be beneficial for many of these conditions, including psoriasis, systemic sclerosis and Sjogren’s. Hashimoto’s can benefit from customized thyroid replacement. Biotin and methylcobalamin have been used in MS as well. Ketotifen and cromolyn sodium can benefit patients dealing with mast cell disorders. We will cover different options to help better tailor care for these patients.

    1.5 pharmacy CEUs approved by OBNM

  • Celiac Disease - Research Update for an Underdiagnosed Condition

    Presenter: Lisa Shaver, ND, LAc
    Original Date: November 6, 2021

    Gluten became a household word in the 2000’s along with the revelation that celiac disease is a common condition, more common than rheumatoid arthritis. Despite the prevalence figures, celiac disease continues to be underdiagnosed in the US. Perhaps 6 out of every 50 patients you see has celiac disease. Sadly, we have only succeeded in diagnosing an estimated 20% of all celiacs in the United States.
    Research continues robustly, and the complexities of this permanent autoimmune inflammatory disease continue to be revealed. Dr Shaver will guide you on an update of the recent research on celiac disease touching on the microbiome, viral and bacterial risk factors, inflammatory implications and presentation.
    Research on pharmaceutical investigative treatment candidates in phase II/III clinical trials will be discussed.

    0.25 pharmacy and 1.25 general CEUs approved by OBNM

  • Research Update: Efficacy of the Autoimmune Protocol for IBD & Hashimoto's Disease

    Presenters: Mickey Trescott, FNTP & Angie Alt, NTP, CHC
    Original Date: November 6, 2021

    With autoimmune disease affecting over 50 million Americans, practitioners are likely to regularly see patients struggling with low quality of life due to autoimmunity and find the management of their cases is often complex. The Autoimmune Protocol (AIP), a science-based elimination and reintroduction protocol, has anecdotally been a game-changer for thousands of autoimmune patients through elimination of food-driven sources of inflammation and restoration of nutrient sufficiency. In this presentation we go beyond the anecdotal and review the medical research conducted on the protocol to date, introducing practitioners to the mounting evidence that it can significantly change their patient’s trajectory alone or in combination with conventional or naturopathic treatments.

    1.5 general CEUs approved by OBNM

  • A New Look at Fibromyalgia: Emerging Theories of Autoimmunity

    Presenter: Alena Guggenheim, ND
    Original Date: November 7, 2021

    Fibromyalgia has historically and categorically been written off as "not autoimmune”. Emerging data indicates otherwise. This will likely have a profound impact on how we define and treat the disorder.
    Presentation overview:
    Introduction: Historical perspective on diagnosis, proposed pathogenesis, epidemiology
    Currently biomedical approach to treatment including pharmaceutical management: antidepressants, SNRIs; SSRIs; Tricyclics; Anti-Seizure Medicines; muscle relaxers. Medications that are not intended for treatment including opioids
    Emerging data that supports autoimmunity as an underpinning of disease
    Passive transfer studies
    Small fiber neuropathy
    Possible treatment explanations/ modifications (including pharma interactions)
    Possible ramifications for patients
    Includes case study examples

    0.5 pharmacy and 1.0 general CEUs approved by OBNM

  • Case Studies in Grave's, Hashimoto's, and Other Thyroid Issues: Refreshing Our Understanding of lab Testing, Iodine and Other Relevant Issues

    Presenter: Mona Morstein, ND
    Original Date: November 7, 2021

    The thyroid gland and its hormones has impact on all cells in the body. It becomes imbalanced very frequently and understanding how it functions, how to understand the labs related to it, etiological factors for imbalances, and how to treat it is vital to all naturopathic physicians. In this lecture, Dr. Morstein will discuss the thyroid in depth, including treating hypothyroidism, Hashimoto’s thyroiditis and hyperthyroidism (Grave’s disease). Medications for both hypothyroidism and hyperthyroidism will be addressed.
    (Presentation will cover pharmaceuticals, listed below)
    Natural Dessicated thyroids, L-thyroxine, Liothyronine; LDN
    Methimazole/PTU, Propranolol/Atenolol, Tapezza, Corticosteroids; LDN

    1.0 pharmacy and 0.5 general CEUs approved by OBNM

  • Case Study Deep Dive into IBD and Autoimmune Disorders

    Presenter: Ilana Gurevich
    Original Date: November 7, 2021

    0.25 pharmacy and 1.25 general CEUs pending approval by OBNM

  • Uprooting CFS/ME: Clinical Pearls and the Role of AI

    Presenter: Jennifer Tufenkian, ND
    Original Date: November 7, 2021

    ME/CFS is a common illness without a known single causative etiology. With the rise of ‘Long Covid’ this illness is getting more attention both in the media and in the medical community. What causes ME/CFS? A single etiology with an objective parameter for diagnosis is satisfying- but what if we never find it?
    In my personal and professional journey, I have sought the root cause of ME/CFS and have landed on an interactive grouping of 5 root causes. I will discuss these root causes, how to diagnose and treat them effectively. I will offer up an algorithm to help the practitioner find the particular healing path for their patient. We will discuss the potential for autoimmunity as a causative factor for ME/CFS as well as considerations to assess and treat Long-Covid. We will look at specific cases to demonstrate realistic expectations and outcomes.

    1.5 general CEUs approved by OBNM

Privacy Policy